NDAINTRAVENOUSPOWDER
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
GOZELLIX (gozetotide) by Innovation Pharmaceuticals is 68 gozetotide binds to psma. Approved for prostate cancer. First approved in 2025.
Drug data last refreshed 20h ago
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows positron emission tomography.
Indications (1)
Company
Worked on GOZELLIX at Innovation Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.